MAPK3 and hepatocellular carcinoma: Furthermore, it has been found that the application of hepatocyte growth factor (HGF) in sorafenib treated HCC cells can activate the proto-oncogene MET, re-stimulate the downstream AKT and extracellular regulated protein kinases (ERK1/2) pathways, therefore inhibiting apoptosis.